Ki Y. Chung

8.1k total citations · 1 hit paper
62 papers, 2.4k citations indexed

About

Ki Y. Chung is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Ki Y. Chung has authored 62 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 10 papers in Surgery. Recurrent topics in Ki Y. Chung's work include Colorectal Cancer Treatments and Studies (17 papers), Pancreatic and Hepatic Oncology Research (9 papers) and Cancer Immunotherapy and Biomarkers (9 papers). Ki Y. Chung is often cited by papers focused on Colorectal Cancer Treatments and Studies (17 papers), Pancreatic and Hepatic Oncology Research (9 papers) and Cancer Immunotherapy and Biomarkers (9 papers). Ki Y. Chung collaborates with scholars based in United States, United Kingdom and Germany. Ki Y. Chung's co-authors include Leonard B. Saltz, Deborah Schrag, Jinru Shia, David S. Klimstra, Manish A. Shah, David P. Kelsen, Nancy E. Kemeny, Audrey Hamilton, Daniel Fridman and Dorothy W. Pan and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Ki Y. Chung

61 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry

2005 848 citations Ki Y. Chung, Jinru Shia et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Ki Y. Chung

Since Specialization

Citations

This map shows the geographic impact of Ki Y. Chung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ki Y. Chung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ki Y. Chung more than expected).

Fields of papers citing papers by Ki Y. Chung

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ki Y. Chung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ki Y. Chung. The network helps show where Ki Y. Chung may publish in the future.

Co-authorship network of co-authors of Ki Y. Chung

This figure shows the co-authorship network connecting the top 25 collaborators of Ki Y. Chung. A scholar is included among the top collaborators of Ki Y. Chung based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ki Y. Chung. Ki Y. Chung is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours 2025 ·PubMed ·J. Randolph Hecht, Jean‐Marie Michot, David J. Bajor, Amita Patnaik, Ki Y. Chung, Judy Wang, Gerald S. Falchook, James M. Cleary, Richard D. Kim, Anuradha Krishnamurthy, Omkar Marathe, Hagop Youssoufian, (unknown), (unknown), Srimoyee Ghosh, Hailei Zhang, (unknown), (unknown), Iván Díaz-Padilla, Susanna V. Ulahannan	1
2	First-in-human phase I study of EMB-02, a bispecific antibody targeting PD-1 and LAG-3 in patients with advanced solid tumors 2025 ·British Journal of Cancer ·Daphne Day, Vinod Ganju, Ki Y. Chung, Lu Si, Lili Mao, Morteza Aghmesheh, Robert J. Hoyer, (unknown), (unknown), (unknown), Qiaoyang Lu, Chengjun Jiang, (unknown), (unknown), Jun Guo	3
3	NSABP C-14/Exact Sciences 16-002: CORRECT-MRD II—Second colorectal cancer clinical validation study to predict recurrence using a circulating tumor DNA assay to detect minimal residual disease. 2024 ·Journal of Clinical Oncology ·Mohamed E. Salem, Shannon L. Puhalla, Thomas J. George, Carmen J. Allegra, Bradley A. Arrick, Melanie R. Palomares, Ki Y. Chung, (unknown), (unknown), Frederick L. Baehner, Norman Wolmark	0
4	1028P Preliminary phase I results from a first-in-human study of EMB-02, a PD-1xLAG-3 bispecific antibody, in patients (pts) with advanced solid tumors 2023 ·Annals of Oncology ·Daphne Day, Vinod Ganju, Ki Y. Chung, Lu Si, Limin Mao, Morteza Aghmesheh, Robert J. Hoyer, (unknown), Song Zeng, (unknown), Cui Jiang, Renhai Feng, (unknown), Jin Guo	4
5	LBA-1 The Phase III Study: Targeted intra-arterial gemcitabine vs. continuation of IV gemcitabine plus nab-paclitaxel following induction with sequential IV gemcitabine plus nab-paclitaxel and radiotherapy for locally advanced pancreatic cancer (TIGeR-PaC) 2023 ·Annals of Oncology ·Michael J. Pishvaian, Charles D. Lopez, Emmanuel E. Zervos, Hassan Hatoum, Daniel Berg, (unknown), Brian A. Boone, Thomas Johnson, Amer H. Zureikat, (unknown), Ki Y. Chung, Ripal Gandhi, (unknown), Neehar D. Parikh, Paula M. Novelli, (unknown), Christopher J. Laing, Susan E. Bates, Ramtin Agah, Karyn A. Goodman	1
6	Abstract CT084: Targeted intra-arterial gemcitabine vs. continuation of IV gemcitabine plus nab-paclitaxel following Induction with sequential IV gemcitabine plus nab-paclitaxel and radiotherapy for unresectable locally advanced pancreatic cancer (TIGeR-PaC) - phase III trial interim analysis 2023 ·Cancer Research ·Michael J. Pishvaian, Amer H. Zureikat, Charles D. Lopez, Kenneth Meredith, Emmanuel E. Zervos, Hassan Hatoum, Ki Y. Chung, Daniel Berg, (unknown), Ripal Gandhi, (unknown), (unknown), Paula M. Novelli, (unknown), (unknown), Brian A. Boone, (unknown), Susan E. Bates, Karyn A. Goodman, Ramtin Agah	1
7	Toxicity and efficacy of stereotactic body radiation therapy vs. intensity-modulated radiation therapy for the treatment of locally advanced pancreatic cancer in a phase 3 trial. 2023 ·Journal of Clinical Oncology ·Karyn A. Goodman, Michael J. Pishvaian, Charles D. Lopez, Kenneth Meredith, Emmanuel E. Zervos, Hassan Hatoum, Ki Y. Chung, (unknown), Daniel Berg, (unknown), (unknown), (unknown), Nainesh Parikh, (unknown), (unknown), Brian A. Boone, (unknown), Ramtin Agah, Amer H. Zureikat	1
8	NSABP C-14: CORRECT-MRD II—Second colorectal cancer clinical validation study to predict recurrence using a circulating tumor DNA assay to detect minimal residual disease. 2023 ·Journal of Clinical Oncology ·Mohamed E. Salem, Shannon L. Puhalla, Thomas J. George, Carmen J. Allegra, Bradley A. Arrick, Melanie R. Palomares, Ki Y. Chung, (unknown), (unknown), Frederick L. Baehner, Norman Wolmark	1
9	Targeted intra-arterial gemcitabine vs. continuation of IV gemcitabine plus nab-paclitaxel following induction with sequential IV gemcitabine plus nab-paclitaxel and radiotherapy for unresectable locally advanced pancreatic cancer (TIGeR-PaC): A randomized phase 3 multicenter study. 2023 ·Journal of Clinical Oncology ·Michael J. Pishvaian, Amer H. Zureikat, Charles D. Lopez, Kenneth Meredith, Emmanuel E. Zervos, Hassan Hatoum, Ki Y. Chung, Daniel Berg, (unknown), Ripal Gandhi, (unknown), Nainesh Parikh, Paula M. Novelli, (unknown), (unknown), Brian A. Boone, (unknown), Susan E. Bates, Ramtin Agah, Karyn A. Goodman	1
10	Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors 2022 ·Investigational New Drugs ·Xiaofei Zhou, Ulka N. Vaishampayan, Devalingam Mahalingam, R. Donald Harvey, Ki Y. Chung, Farhad Sedarati, (unknown), Douglas V. Faller, Karthik Venkatakrishnan, Neeraj Gupta	7
11	Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53 2021 ·Clinical Cancer Research ·Mansoor N. Saleh, Manish R. Patel, Todd M. Bauer, Sanjay Goel, Gerald S. Falchook, Geoffrey I. Shapiro, Ki Y. Chung, Jeffrey R. Infante, Robert M. Conry, Guilherme Rabinowits, David S. Hong, Judy S. Wang, Ulrich Steidl, Gurudatta Naik, Vincent Guerlavais, Vojislav Vukovic, D. Allen Annis, Manuel Aivado, Funda Meric‐Bernstam	110
12	A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer 2021 ·Lung Cancer ·Ruth Plummer, Emma Dean, Hendrik‐Tobias Arkenau, Charles H. Redfern, Alexander I. Spira, Jason M. Melear, Ki Y. Chung, (unknown), Thomas Goddemeier, Giuseppe Locatelli, Jennifer Dong, Patricia Fleuranceau-Morel, Iván Díaz-Padilla, Geoffrey I. Shapiro	26
13	Safety and clinical activity of durvalumab in combination with tremelimumab in extensive disease small-cell lung cancer (ED-SCLC). 2018 ·Journal of Clinical Oncology ·Daniel C. Cho, Amit Mahipal, Afshin Dowlati, Warren Chow, Neil H. Segal, Ki Y. Chung, Bryan J. Schneider, John Nemunaitis, Albiruni Ryan Abdul Razak, Frank Tsai, Ani Sarkis Balmanoukian, Lyudmila Bazhenova, Feng Xiao, Natasha Angra, Shaad E. Abdullah, Jason J. Luke	29
14	A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma 2011 ·Cancer Chemotherapy and Pharmacology ·Ana De Jesus‐Acosta, George R. Oliver, Amanda L. Blackford, (unknown), (unknown), Lalan S. Wilfong, Lei Zheng, Ross C. Donehower, David Cosgrove, Daniel A. Laheru, Dung T. Le, Ki Y. Chung, Luis A. Díaz	29
15	G3139 (Genasense) in Patients With Advanced Merkel Cell Carcinoma 2009 ·American Journal of Clinical Oncology ·Manisha H. Shah, Kimberly A. Varker, Minden Collamore, James A. Zwiebel, Daniel Coit, David P. Kelsen, Ki Y. Chung	34
16	NUP98 Dysregulation in Myeloid Leukemogenesis 2007 ·Annals of the New York Academy of Sciences ·Malcolm A.S. Moore, Ki Y. Chung, Magdalena Plašilová, Jan Jacob Schuringa, J.‐H. SHIEH, Pengbo Zhou, Giovanni Morrone	46
17	Enforced Expression of NUP98-HOXA9 in Human CD34+ Cells Enhances Stem Cell Proliferation 2006 ·Cancer Research ·Ki Y. Chung, Giovanni Morrone, Jan Jacob Schuringa, Magdalena Plašilová, Jae-Hung Shieh, Yue Zhang, Pengbo Zhou, Malcolm A.S. Moore	57
18	Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study 2005 ·Modern Pathology ·Jinru Shia, David S. Klimstra, Allan R. Li, Jing Qin, Leonard B. Saltz, Julie Teruya‐Feldstein, Muzaffar Akram, Ki Y. Chung, Davis X. Yao, Philip B. Paty, William L. Gerald, Beiyun Chen	127
19	Cetuximab Therapy and Symptomatic Hypomagnesemia 2005 ·JNCI Journal of the National Cancer Institute ·Deborah Schrag, Ki Y. Chung, Carlos D. Flombaum, Leonard B. Saltz	175
20	Hypereosinophilic syndrome on the extremities associated with abnormal peripheral blood circulation 1995 ·Linchuang pifuke zazhi ·(unknown), Ik Jae Lee, Ki Y. Chung, (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact